TG Therapeutics (TGTX) has just released its preliminary U.S. BRIUMVI net product revenue figures for the fourth quarter of 2023 and the entire year. The company is thrilled to announce that it anticipates a net product revenue of around $40 million for the fourth quarter and an impressive $89 million for the entire year. These numbers are a testament to the hard work and dedication of the TG Therapeutics team.
Looking ahead to the future, TG Therapeutics has set ambitious goals for the fiscal year 2024. The company aims to achieve BRIUMVI U.S. net product revenue ranging from $41 to $46 million for the first quarter alone. As for the full year, TG Therapeutics is targeting an even more substantial net product revenue of $220 to $260 million.
These projections demonstrate the company’s confidence in the continued success and growth of the BRIUMVI product line. TG Therapeutics is excited about the opportunities that lie ahead and remains committed to providing innovative solutions to patients in need.
January 10, 2024
[bs_slider_forecast ticker=”TGTX”]
TG Therapeutics Inc. (TGTX) Stock Performance: January 10, 2024 Analysis and Insights
TG Therapeutics Inc. (TGTX) experienced a mixed performance on January 10, 2024. The price of TGTX shares dropped significantly by $3.49, representing a 16.61% decrease since the market closed. However, the stock opened at $22.62, which was $1.61 higher than its previous close. TGTX’s position above its 200-day simple moving average suggests that the stock has maintained a relatively stable performance over the long term. However, investors should dig deeper into the company’s financials and news releases to better understand the reasons for this decline. The stock’s opening price of $22.62 indicates some initial optimism among investors, but it is important to monitor the stock’s performance throughout the day for a more comprehensive understanding.
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”TGTX” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]
TG Therapeutics (TGTX) Stock Performance: Mixed Revenue Results and Improved Net Income
TG Therapeutics (TGTX) has experienced mixed performance in its stock prices on January 10, 2024. As per the data sourced from CNN Money, TGTX reported a total revenue of $2.79 million over the past year, which represents a significant decrease of 58.36% compared to the previous year. However, the company witnessed a substantial increase of 931.57% in its total revenue since the last quarter, reaching $165.81 million.
Despite the decline in total revenue over the past year, TGTX managed to improve its net income. The company reported a net loss of -$198.34 million in the previous year, but this figure has significantly improved by 43.02% to $113.93 million in the third quarter of the current year. Furthermore, TGTX experienced a remarkable increase of 339.3% in net income since the last quarter.
When analyzing the earnings per share (EPS) of TGTX, it becomes evident that the company has made positive strides. Over the past year, the EPS stood at -$1.46, but it has increased by 44.37% to reach $0.73 in the third quarter of the current year. Similarly, in comparison to the previous quarter, the EPS surged by 317.21%.
These financial indicators reflect a mixed performance for TGTX on January 10, 2024. While the company witnessed a decline in total revenue over the past year, it experienced a significant increase in revenue since the last quarter. Additionally, TGTX managed to improve its net income, with a substantial increase since the last quarter. The positive trend continues with the company’s EPS, which has shown consistent growth both annually and quarterly.
Investors should take note of these financial metrics when considering TGTX as an investment option. While the decline in total revenue over the past year might raise concerns, the significant increase in revenue and net income since the last quarter indicates potential growth opportunities. Furthermore, the consistent growth in EPS suggests that TGTX has been able to improve its profitability.
However, it is important to conduct further research and analysis to understand the underlying factors contributing to TGTX’s financial performance. Factors such as product developments, market conditions, and competition can greatly impact the future prospects of the company. Therefore, investors should exercise caution and consult with financial advisors before making any investment decisions regarding TGTX stock.
